Evaluation of lymphocyte therapy effects on treatment of women with unexplained Recurrent Spontaneous Abortion (RSA)
Not Applicable
- Conditions
- Recurrent spontaneous abortion.(O31.1)
- Registration Number
- IRCT20201126049497N2
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 50
Inclusion Criteria
The age range from 18 to 35 years
The presence of repeated miscarriages with unknown reasons and the possibility of immunological reasons
Presence of APCA antibody percentage lower than 5%
Exclusion Criteria
Presence of abortion with known non-immunological causes
Presence of APCA antibody percentage higher than 5%
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method o abortion and successful pregnancy. Timepoint: Before the intervention and after the intervention. Method of measurement: The number of births resulting in the birth of a healthy baby.
- Secondary Outcome Measures
Name Time Method APCA antibody percentage. Timepoint: At intervals of 3 weeks and up to 3 times. Method of measurement: complement-dependent cytotoxicity method.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie lymphocyte therapy's efficacy in treating unexplained recurrent spontaneous abortion (RSA)?
How does lymphocyte therapy compare to standard-of-care treatments like corticosteroids for RSA in clinical outcomes?
Which biomarkers, such as Th1/Th2 cytokine ratios or regulatory T cell levels, predict response to lymphocyte therapy in RSA patients?
What are the potential adverse events associated with lymphocyte therapy in RSA, and how are they managed clinically?
Are there combination approaches involving lymphocyte therapy and immunomodulators for improving pregnancy outcomes in RSA?